WASHINGTON — Sen. Ron Wyden (D-Ore.), the influential chair of the Senate Finance Committee, is promising that his signature drug pricing package won’t eviscerate small biotech companies.
Wyden, typically a fierce critic of the drug industry, is suddenly giving a shoutout to small biotech companies and their role in developing “groundbreaking new treatments.” He’s even promising that the package he is crafting “can be tailored to the scale of these companies, as well as other factors that affect their access to capital.”
The shocking promise came in a three-page white paper released Tuesday outlining his five “principles for drug pricing reform.” It’s the opening salvo in Wyden’s quest to craft a drug pricing package that can finally be sent to the president’s desk.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
